Press releases
-
September 10, 2026
Adneuris Therapeutics Presents Novel Data on Lead Candidate, Cebranopadol for the Treatment of Moderate-to-Severe Acute Pain at PAINWeek 2026
-
September 3, 2026
Adneuris Therapeutics to Present at PAINWeek 2026
-
August 5, 2026
Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea
-
July 14, 2026
Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
-
July 9, 2026
Tris Pharma Launches Adneuris Therapeutics to Advance a New Era in Pain Medicine
-
March 6, 2026
Tris Pharma Announces Positive Debut Data from Phase 3 ALLEVIATE-1 and 2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
-
February 26, 2026
Tris Pharma to Present Debut Data from Phase 3 ALLEVIATE 1-2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
-
January 8, 2026
Tris Pharma Announces Acceptance of New Publication Highlighting Promise of Dual NOP-MOP (dual-NMR) Agonists for the Treatment of Moderate-to-Severe Pain
-
August 28, 2025
Tris Pharma Showcases a Novel Mechanism of Dual-NOP/MOP (NMR) Agonism for the Treatment of Moderate-to-Severe Acute Pain and Encores Positive Phase 3 Data at 2025 Annual PAINWeek Meeting in Las Vegas
-
June 12, 2025
Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting
